Associate Director
Frontier Medicines, Inc, California, United States
Michael Shaghafi, PhD, Associate Director, Medicinal and Platform Chemistry, Frontier Medicines.
Mike is a trained Medicinal Chemist, with experience in structure-based drug design, ligand-based methods, covalent chemistries, and targeted-protein degradation. Mike began his industrial career at eFFECTOR Therapeutics, contributing to the discovery of small-molecule selective translational regulator inhibitors for indications in oncology and immuno-oncology. He next transitioned to Abide Therapeutics, a chemoproteomic drug discovery organization which centered on the development of covalent compounds for the pharmcological interrogation of the metabolic serine hydrolase class of enzymes. Mike is a co-inventor of ABX-1762 (now Lu AG06479; Lundbeck), a selective MGLL follow-on inhibitor.
In 2019 Mike began his career at Frontier Medicines, a chemoproteomic drug discovery company, aimed at targeting well-validated driver and classically undruggable proteins for indications in oncology. Mike’s current research interests are focused on progressing chemical matter arising from Frontier’s proprietary covalent collection toward advanced leads and candidates for undruggable and unmet medical need.
Mike received his PhD in asymmetric method development (Prof. Elizabeth Jarvo, UC Irvine), followed by a postdoctoral assignment in methods toward expanded natural product alkaloid frameworks (Prof. Larry E. Overman, UC Irvine).
Disclosure information not submitted.
Wednesday, February 9, 2022
10:00 AM – 11:30 AM